Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
27,795,576
-
Total 13F shares
-
18,728,083
-
Share change
-
-3,713,236
-
Total reported value
-
$18,593,968
-
Put/Call ratio
-
2760%
-
Price per share
-
$0.99
-
Number of holders
-
65
-
Value change
-
-$4,851,056
-
Number of buys
-
20
-
Number of sells
-
60
Institutional Holders of Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) as of Q2 2022
As of 30 Jun 2022,
Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) was held by
65 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
18,728,083 shares.
The largest 10 holders included
GRIFFIN ASSET MANAGEMENT, INC., ORACLE INVESTMENT MANAGEMENT INC, VANGUARD GROUP INC, Birchview Capital, LP, CITADEL ADVISORS LLC, Cannell & Co., Cladis Investment Advisory, LLC, BlackRock Inc., JPMORGAN CHASE & CO, and Belpointe Asset Management LLC.
This page lists
65
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.